- Home
- QCLS vs NRSN Comparison
QCLS vs NRSN Comparison
Compare QCLS & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QCLS | NRSN |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | Israel |
| Employees | 2 | 16 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 25.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | QCLS | NRSN |
|---|---|---|
| Price | $3.63 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 240.8K | 198.8K |
| Earning Date | 04-15-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $0.63 |
| 52 Week High | $8.17 | $2.11 |
Technical Indicators
Market Signals| Indicator | QCLS | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 44.37 |
| Support Level | $3.45 | $0.67 |
| Resistance Level | $3.90 | $0.75 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 15.87 | 17.17 |
Price Performance
Historical ComparisonAbout QCLS Q/C Technologies Inc.
Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.